Logo image of CYCCP

CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) Stock Fundamental Analysis

NASDAQ:CYCCP - Nasdaq - US23254L2079 - Currency: USD

7.39  -0.55 (-6.93%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CYCCP. CYCCP was compared to 571 industry peers in the Biotechnology industry. Both the profitability and financial health of CYCCP have multiple concerns. CYCCP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CYCCP has reported negative net income.
In the past year CYCCP has reported a negative cash flow from operations.
CYCCP had negative earnings in each of the past 5 years.
CYCCP had a negative operating cash flow in each of the past 5 years.
CYCCP Yearly Net Income VS EBIT VS OCF VS FCFCYCCP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

CYCCP has a worse Return On Assets (-250.53%) than 92.90% of its industry peers.
Industry RankSector Rank
ROA -250.53%
ROE N/A
ROIC N/A
ROA(3y)-127.03%
ROA(5y)-93.46%
ROE(3y)-1302.39%
ROE(5y)-802.63%
ROIC(3y)N/A
ROIC(5y)N/A
CYCCP Yearly ROA, ROE, ROICCYCCP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CYCCP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYCCP Yearly Profit, Operating, Gross MarginsCYCCP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K

More info and screens

1

2. Health

2.1 Basic Checks

CYCCP does not have a ROIC to compare to the WACC, probably because it is not profitable.
CYCCP has less shares outstanding than it did 1 year ago.
CYCCP has more shares outstanding than it did 5 years ago.
CYCCP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CYCCP Yearly Shares OutstandingCYCCP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
CYCCP Yearly Total Debt VS Total AssetsCYCCP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -114.94, we must say that CYCCP is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -114.94, CYCCP is not doing good in the industry: 97.87% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -114.94
ROIC/WACCN/A
WACC9.52%
CYCCP Yearly LT Debt VS Equity VS FCFCYCCP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M 30M

2.3 Liquidity

CYCCP has a Current Ratio of 0.77. This is a bad value and indicates that CYCCP is not financially healthy enough and could expect problems in meeting its short term obligations.
CYCCP has a worse Current ratio (0.77) than 91.30% of its industry peers.
CYCCP has a Quick Ratio of 0.77. This is a bad value and indicates that CYCCP is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.77, CYCCP is not doing good in the industry: 91.30% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.77
Quick Ratio 0.77
CYCCP Yearly Current Assets VS Current LiabilitesCYCCP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

6

3. Growth

3.1 Past

CYCCP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 68.67%, which is quite impressive.
Looking at the last year, CYCCP shows a very negative growth in Revenue. The Revenue has decreased by -80.83% in the last year.
Measured over the past years, CYCCP shows a very strong growth in Revenue. The Revenue has been growing by 22.87% on average per year.
EPS 1Y (TTM)68.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.55%
Revenue 1Y (TTM)-80.83%
Revenue growth 3YN/A
Revenue growth 5Y22.87%
Sales Q2Q%-37.5%

3.2 Future

CYCCP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.14% yearly.
The Revenue is expected to grow by 213.65% on average over the next years. This is a very strong growth
EPS Next Y92.7%
EPS Next 2Y39.85%
EPS Next 3Y25.1%
EPS Next 5Y17.14%
Revenue Next Year-86.38%
Revenue Next 2Y-49.3%
Revenue Next 3Y-36.42%
Revenue Next 5Y213.65%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CYCCP Yearly Revenue VS EstimatesCYCCP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
CYCCP Yearly EPS VS EstimatesCYCCP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -1K -2K -3K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CYCCP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYCCP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYCCP Price Earnings VS Forward Price EarningsCYCCP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYCCP Per share dataCYCCP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

CYCCP's earnings are expected to grow with 25.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.85%
EPS Next 3Y25.1%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CYCCP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYCLACEL PHARMACEUTICALS - CYCC 6 PERP

NASDAQ:CYCCP (2/21/2025, 8:11:33 PM)

7.39

-0.55 (-6.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-17 2025-03-17/amc
Inst Owners18.63%
Inst Owner Change89.36%
Ins Owners2.48%
Ins Owner ChangeN/A
Market Cap83.21M
Analysts43.33
Price Target18.95 (156.43%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.03
Dividend Growth(5Y)-38.18%
DP-0.37%
Div Incr Years0
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)59.51%
Min EPS beat(2)50.81%
Max EPS beat(2)68.2%
EPS beat(4)3
Avg EPS beat(4)42.12%
Min EPS beat(4)-3.64%
Max EPS beat(4)68.2%
EPS beat(8)5
Avg EPS beat(8)19.9%
EPS beat(12)9
Avg EPS beat(12)22.73%
EPS beat(16)10
Avg EPS beat(16)7.81%
Revenue beat(2)1
Avg Revenue beat(2)4.58%
Min Revenue beat(2)-86.93%
Max Revenue beat(2)96.08%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-73.63%
EPS NQ rev (1m)0%
EPS NQ rev (3m)88.8%
EPS NY rev (1m)0%
EPS NY rev (3m)37.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)23.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1124.48
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-9.4
EYN/A
EPS(NY)-1.2
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS0.01
BVpS-0.09
TBVpS-0.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -250.53%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-127.03%
ROA(5y)-93.46%
ROE(3y)-1302.39%
ROE(5y)-802.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.77
Quick Ratio 0.77
Altman-Z -114.94
F-Score2
WACC9.52%
ROIC/WACCN/A
Cap/Depr(3y)42.56%
Cap/Depr(5y)135.54%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.55%
EPS Next Y92.7%
EPS Next 2Y39.85%
EPS Next 3Y25.1%
EPS Next 5Y17.14%
Revenue 1Y (TTM)-80.83%
Revenue growth 3YN/A
Revenue growth 5Y22.87%
Sales Q2Q%-37.5%
Revenue Next Year-86.38%
Revenue Next 2Y-49.3%
Revenue Next 3Y-36.42%
Revenue Next 5Y213.65%
EBIT growth 1Y46.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y47.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.83%
OCF growth 3YN/A
OCF growth 5YN/A